Biofil Chemicals & Pharmaceuticals (BCPL) was formally created and deployed as a legal entity as a private limited company on 4 Jan.'85 for manufacture of pharmaceutical products and it was converted into a public limited company on 7 May '92. It was promoted by the Systematix group and Ramesh Shah of the Cyano group. Ramesh Shah is the chairman and managing director and Anand Kumar Sethiya is the managing director.

In Feb.'96, the company had come out with a rights-cum-public issue at a premium of Rs 7.50 and at a premium of Rs 12.50 respectively, both aggregating Rs 23.21 cr, to part-finance its expansion and diversification into bulk drugs and pharmaceutical formulations. The company currently manufactures pharmaceutical formulations like injections, capsules, eye-drops and dry syrups at its plant located in Indore.

BCPL's new unit is being created and deployed at Pithampur in Madhya Pradesh at a project cost of Rs 39.75 cr and will manufacture bulk drugs like astemizole, cefaclor, pentazocine, cefazolin sodium and cefotoxime sodium. It is also setting up a R&D centre which will include a pilot plant for bulk drugs and separate sections for formulations development and will house modern analytical instruments.

During the year 1999-2000, the company had achieved a turnover of Rs.1164.03 lakhs.